drugset / Trial / NCT05227144
Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to establish the Recommended Phase 2 Dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antimyeloma activity of ORIC-533 in patients with multiple myeloma who have exhausted available treatment options
Timeline
- Start
- 2022-01-06
- Primary completion
- 2025-03-03
- Completion
- 2025-03-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ORIC-533 | Small molecule | — | Oral |